Company: ABBV
Filing Date: 2025-02-14
Form Type: 10-K
Source: 0001551152-25-000020
Chunk: 315

Company: AbbVie Inc.
Filing Date: 2025-02-14
Form: 10-K
Item: Item 8
Chunk 315
---
 

2024 Form 10-K   |  62

Note 4 Earnings Per Share

AbbVie grants certain restricted stock units (RSUs) that are considered to be participating securities. Due to the presence of participating securities, AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For all periods presented, the two-class method was more dilutive. The following table summarizes the impact of the two-class method:Years ended December 31,(in millions, except per share data)202420232022Basic EPSNet earnings attributable to AbbVie Inc.$4,278 $4,863 $11,836 Earnings allocated to participating securities40 43 54 Earnings available to common shareholders$4,238 $4,820 $11,782 Weighted average basic shares of common stock outstanding1,769 1,768 1,771 Basic earnings per share attributable to AbbVie Inc.$2.40 $2.73 $6.65 Diluted EPSNet earnings attributable to AbbVie Inc.$4,278 $4,863 $11,836 Earnings allocated to participating securities40 43 54 Earnings available to common shareholders$4,238 $4,820 $11,782 Weighted average shares of common stock outstanding1,769 1,768 1,771 Effect of dilutive securities4 5 7 Weighted average diluted shares of common stock outstanding1,773 1,773 1,778 Diluted earnings per share attributable to AbbVie Inc.$2.39 $2.72 $6.63 Certain shares issuable under stock-based compensation plans were excluded from the computation of EPS because the effect would have been antidilutive. The number of common shares excluded was insignificant for all periods presented.

Note 5 Licensing, Acquisitions and Other Arrangements

Acquisition of Cerevel Therapeutics Holdings, Inc.On August 1, 2024, AbbVie completed its previously announced acquisition of Cerevel Therapeutics. Cerevel Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of differentiated therapies for neuroscience diseases. Cerevel Therapeutics neuroscience pipeline includes multiple clinical-stage and preclinical candidates with the potential to treat several diseases including schizophrenia, Parkinson's disease and mood disorders. Under the terms of